SmartTRAK: Hi, this is David Shepard with SmartTRAK. I'm here with Ben Browne, national sales director for TendoNova. Ben, tell me a little bit about the product and how things are going at the booth today.

Ben Browne: So, it's a great conference, very active, most of the conference so far. And TendoNova is essentially a device that providers are going to use, perhaps instead of or in addition to orthobiologics, to treat a common refractory tendinopathy patient. A patient who's perhaps failed conservative therapies, they've dealt with tendinopathy or tendinosis for at least three months, in some cases, many months. And once again, they failed many conservative therapies. What's great about TendoNova is that ..

Click the button to get the full transcript of our exclusive interview with TendoNova's National Sales Director Ben Browne conducted by David Shepard, SmartTRAK GM/Sr Analyst, Orthobio & Regen.

Christina Goudy, co-founder and CEO of Reach Orthopaedics, discusses the company and its new subacromial spacer device in an interview with SmartTRAK.

In a recent interview with SmartTRAK, Christina Goudy, co-founder and CEO of Reach Orthopaedics, discussed the company’s new subacromial (SA) spacer for the treatment of massive, irreparable rotator cuff tears, its strategic direction and company highlights.

To find out more about the company, its differentiated technologies, products and growth strategy, click on the following video (26:57 min). Interview topics by timecode are provided below, as is a link to download a complete transcript of the interview.

Interview Outline by Timecode:

• 00:50  Introduction to Reach Orthopaedics and Christina Goudy.
• 03:15  Image of SA spacer device.
• 07:05  Christina’s background and running a med device startup.
• 14:48  Age of the company, FDA pathway and funding.
• 18:16  Goal for sales to start.
• 19:42  What the surgeons are saying about the device, specs and sizes.
• 23:40  Exit strategy.

Click the button below to download and read the complete transcript of SmartTRAK's interview with Christina Goudy, co-founder and CEO of Reach Orthopaedics, conducted by  Andy Knapik, SmartTRAK Sr. Analyst, Soft Tissue & Arthroscopic Technologies.

SmartTRAK spotlights Pristine Surgical in an interview at AANA 2025 in Washington, DC. 

Bryan Lord, CEO of Pristine Surgical, discussed the company’s Summit 4K, single-use arthroscopic camera in an interview with SmartTRAK at the Arthroscopy Association of North America (AANA) 2025 Meeting in Washington, D.C . 

Watch the following video to learn more about Pristine Surgical and its novel technology. (21:27 min.) A link to download a complete transcript of the interview is also provided below. 

Hey, everybody, it's Andy Knapik, Senior Analyst for SmartTRAK for all things sports medicine and arthroscopy. I'm here at the AANA meeting in Washington, D.C. We're at the Pristine Surgical booth. I'm joined by Bryan Lord, CEO of Pristine Surgical, and here just to talk about what they have going on. They have a single-use arthroscopic camera.

Bryan, I've known you now for probably a few years, we've talked about this quite a bit. When we look in the video capital world, we see a lot of different things going on right now. We have traditional capital systems like the Strykers, and Smith+Nephews, Arthrexes of the world, with a full tower. We have some wireless options out there now that are pretty intriguing. And then we have some single-use options. Arthrex has a nanoscope and then you guys have yours as well.

So, talk about how this got started, what benefits you initially saw, and how is that progressing now.

BL: Yes, so the genesis of the scope that we see here today actually was in a rather niche application. Some docs said, ‘Look, we think we could do some things different in visualization.’ And they were looking for ways to do some different angular types of views, 30, 70, in more of a pannable configuration. The early days of the development we did in partnership with a group called DECA Research in Manchester, New Hampshire, led by the noted medtech developer and entrepreneur engineer, Dean Kamen. In the conversation with those doctors and Dean, the concept came up (Dean's idea) to say, ‘Look, we think that we could do this single use. Would that be interesting?’

At that time, it was still early in the ways that people were understanding the proliferation of digital technologies, but everybody knew, including Dean, who's always been in the forefront, this was really a big idea. How could we take today's burgeoning areas of digital photography and bring that into the surgical suite? And it was early on that we knew that it was ...

Click the button below to download and read the complete transcript of SmartTRAK's interview with Bryan Lord, CEO of Pristine Surgical, conducted by  Andy Knapik, SmartTRAK Senior Analyst, Soft Tissue Fixation and Arthroscopic Enabling Technologies.

Soft tissue and cartilage repair trends and innovations take center stage.

Joint restoration and preservation continued to gain attention at this year’s Canaccord Genuity (CG) Musculoskeletal (MSK) Healthcare Conference and at the American Academy of Orthopaedic Surgeons' (AAOS) 2025 Annual Meeting, both in San Diego. From start-ups reporting early results and seeking investors to large companies showcasing recently acquired assets or newly launched products, the meetings were abuzz with companies and healthcare providers aspiring to help patients heal more naturally, restore an active lifestyle and delay joint replacement surgery.

In this market perspective article, SmartTRAK covers everyone from powerhouse names like Smith+Nephew and Stryker to dynamic start-ups, like CytexOrtho, Nanochon and Hyalex Orthopaedics. Their focus was clear: help the body heal naturally and preserve movement for as long as possible.

Below is a preview of the full article. The complete Market Perspective is available for download.

      

SmartTRAK spotlights Tetrous in an interview at AAOS 2025 in San Diego. 

Andy Carter, Chief Technology Officer and Founder of Tetrous, discusses the company’s novel approach to addressing Enthesis Failure Syndrome in an interview with SmartTRAK at the American Academy of Orthopaedic Surgeons (AAOS) 2025 Annual Meeting in San Diego. 

To learn more about Tetrous and its novel technology, listen to the following video. (21:42 min.) A link to download the transcript of the interview is also provided below. 

Hey everybody, it's Andy Knapik, live here at AAOS 2025 in San Diego. Today I'm joined here with a friend, colleague, and someone I've known now for, I guess a couple years, Andy Carter, Founder, Chief Technology Officer of a company called Tetrous, which is really some exciting biologic technology. So I just brought him along. We're going to chat a little bit about it. So Andy, why don't you just tell everybody what it is about Tetrous and what you guys do and why it's so great.

Andy Carter: Thanks for the opportunity. It's a great topic to talk about and I really, really love it. So we started Tetrous a couple of years ago. We spun it out of Theracell, the company that we sold to, ISTO Biologics. They're doing great and taking the technology in the spine and doing various things. But along the way, I read quite a few papers about how demineralized bone matrix materials could influence enthesis repair. And that's getting back to sports medicine, which is my roots and well, my real passion. I looked at these papers and they basically showed that demineralized bone matrix materials could influence the enthesis to heal. A tendon, the enthesis, is the bit between the tendon and the bone. It's the junction. It's how you get load transfer between rigid bone and flexible tendon. It's a biological structure that's very exquisite and unique. You look at the histology and the biologists go into raptures and "wows" about it and whatever.

The fundamentals are that you've got collagen fibers going from the bone through into the tendon. That's what gives you the strength. You see them in the histology with Sharpey's fibers. If you just reattach tendon to bone, you just get scar tissue. Scar tissue is not as strong. Basically, it pulls out and thins and fails with time. So part of the reason that we see so many problems with rotator cuff repair is that nobody's doing anything to heal the enthesis. There was this literature out there saying, ‘Hey, you can use DBM for this,’ but none of the papers showed it in any way that was something that you could see a surgeon being able to use-

Right, a practical form.

AC: There's one group, guys I know very well had used DBM powder. Now DBM powder, you can do it in a rat study and show that it works, but that's not a product. So what we were able to do, one of the clever things about the technology that we developed at Theracell, the fiber technology is, it allows us to ....

Click the button below to download and read the complete transcript of SmartTRAK's interview with Andy Carter, founder and CTO of Tetrous, conducted by Andy Knapik, SmartTRAK Senior Analyst, Soft Tissue Fixation and Arthroscopic Enabling Technologies.

SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s propriety methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services. If you would like a demo of what SmartTRAK has to offer and see how we can help increase proficiency, improve productivity and reduce costs for your company, just click here.

SmartTRAK highlights key trends and happenings in sports medicine and arthroscopy at AAOS 2024.

The American Academy of Orthopaedic Surgeons (AAOS) convened this year in San Francisco, California, from February 12-16. Following several years of subdued participation due to the COVID-19 pandemic, last year's strong showing at AAOS in Las Vegas fostered expectations for a continuation of momentum this year. Despite lower-than-projected attendance from medical professionals, the event featured a robust presence of large and small companies presenting their products and services. So, what was the buzz at the meeting?

In this Perspective article, which can be downloaded here, SmartTRAK highlights key takeaways from AAOS for companies competing in the Sports Medicine Market, including the following topics:

• Continued Interest in Biologic-driven Soft Tissue Fixation
  Companies are still helping drive soft tissue fixation sales through the use of biologics, which now are key advancements in technology at the forefront of sports medicine surgical procedures. Smith+Nephew continues to drive its Sports Medicine business with ... (read more)
  
  
• Ongoing Focus on the ASC Market
  Companies at AAOS had a prominent focus on the Ambulatory Surgery Center (ASC) Market. According to the SmartTRAK US Ortho ASC Market Overview, as of 2022, there were over ... (read more)
  
  
• Developments in Arthroscopic Technologies
  Another common theme on display across the AAOS 2024 exhibit floor was the showcasing of surgical video technologies. All the big players in sports medicine had their video systems on display, and some notable systems stood out. Stryker highlighted its newest ... (read more)

To download and read the complete "Highlights in Sports Medicine and Arthroscopy from AAOS 2024" Perspective article by Andy Knapik, SmartTRAK Senior Analyst, Soft Tissue Fixation and Arthroscopic Enabling Technologies, just click the button below.